FA Immuno Pharm

Question 1

CU epoetin alfa (erythropoietin)

Answer 1

Anemias, esp in renal failure

Question 2

CU thrombopoietin

Answer 2

Thrombocytopenia

Question 3

CU oprelvekin (IL-11)

Answer 3

Thrombocytopenia

Question 4

CU filgrastim (G-CSF)

Answer 4

Recovery of bone marrow

Question 5

CU sargamostim (GM-CSF)

Answer 5

Recovery of bone marrow

Question 6

CU Aldesleukin (IL-2)

Answer 6

Renal cell carcinoma, metastatic melanoma

Question 7

CU IFN-alpha

Answer 7

Chronic hepatitis B and C,
Kaposi sarcoma,
Hairy cell leukemia, 
condyloma acuminatum,
renal cell carcinoma,
Malignant melanoma

Question 8

CU IFN-beta

Answer 8

MS

Question 9

CU IFN-gamma

Answer 9

CGD

Question 10

Alemtuzumab =

Answer 10

anti-CD52

Question 11

Bevacizumab =

Answer 11

anti-VEGF

Question 12

Cetuximab =

Answer 12

anti-EGFR

Question 13

Rituximab =

Answer 13

anti-CD20

Question 14

Trastuzumab =

Answer 14

anti-HER2/neu

Question 15

CU alemtuzumab

Answer 15

CLL

Question 16

CU bevcizumab

Answer 16

colorectal cancer, RCC

Question 17

CU cetuximab

Answer 17

stage IV colorectal cancer, head and neck cancer

Question 18

CU rituximab

Answer 18

B-cell non-Hodgkin lymphoma,
RA (with MTX),
ITP

Question 19

CU trastuzumab

Answer 19

Breast cancer, gastric cancer

Question 20

Infliximab =

Answer 20

anti-TNF-alpha

Question 21

Adalimumab =

Answer 21

anti-TNF-alpha

Question 22

CU infliximab

Answer 22

IBD, RA, ankylosing spondylitis, psoriasis

Question 23

CU adalimumab

Answer 23

IBD, RA, ankylosing spondylitis, psoriasis

Question 24

Natalizumab =

Answer 24

anti-alpha4-integrin

Question 25

alpha4-integrin is important for:

Answer 25

leukocyte adhesion

Question 26

CU natalizumab

Answer 26

MS, Crohn disease

Question 27

SE natalizumab

Answer 27

risk of PML in patients with JC virus

Question 28

Abciximab =

Answer 28

anti-glycoprotein IIb/IIIa

Question 29

CU abciximab

Answer 29

anti-platelet agent for prevention of ischemic complications in patients undergoing percutaneous coronary intervention

Question 30

Denosumab =

Answer 30

anti-RANKL

Question 31

CU denosumab

Answer 31

osteoporosis: inhibits osteoclast maturation (mimics osteoprotegrin)

Question 32

CU digoxin immune Fab

Answer 32

Antidote for digoxin toxicity

Question 33

Omalizumab =

Answer 33

anti-IgE

Question 34

CU omalizumab

Answer 34

allergic astma: prevents IgE binding to FCepsilonRI (add on therapy)

Question 35

Palivizumab =

Answer 35

anti-RSV F protein;

Question 36

CU palivizumab

Answer 36

RSV prophylaxis for his risk infants

Question 37

Calcineurin inhibitor; binds cyclophilin. Blocks T cell activation by preventing IL-2 transcription

Answer 37

Cyclosporine

Question 38

CU cyclosporine

Answer 38

transplant rejection prophylaxis, psoriasis, RA

Question 39

Tox cyclosporine

Answer 39

- Nephrotoxicity, - HTN, hyperlipidemia, hyperglycemia, - Tremor - Hirsuitism, gingival hyperplasia

Question 40

Calcineurin inhibitor; binds FK506 binding protein (FKBP); blocks T cell activation by preventing IL-2 transcription

Answer 40

Tacrolimus | note that all -limus drugs bind FKBP!

Question 41

CU Tacrolimus

Answer 41

Transplant rejection prophylaxis

Question 42

Tox tacrolimus

Answer 42

- Diabetes & neurotoxicity (more than cyclosporine) - Nephrotoxicity, - HTN, hyperlipidemia, hyperglycemia, - Tremor

Question 43

mTOR inhibitor; binds FKBP; blocks T cell activation and B cell differentiation by preventing IL-2 signal transduction

Answer 43

Sirolimus (rapamycin)

Question 44

CU sirolimus (rapamycin)

Answer 44

kidney transplant rejection prophylaxis

Question 45

Tox sirolimus (rapamycin)

Answer 45

anemia, thrombocytopenia, leukopenia, hyperlipidemia, but NOT nephrotoxic

Question 46

Basiliximab =

Answer 46

anti-IL-2R

Question 47

CU Basiliximab

Answer 47

kidney transplant prophylaxis

Question 48

Tox Basiliximab

Answer 48

Edema, HTN, tremor

Question 49

Antimetabolite precursor of 6-MP; inhibits lymphocyte proliferation by blocking nucleotide synthesis

Answer 49

Azathioprine

Question 50

CU azathioprine

Answer 50

transplant rejection prophylaxis; RA; Crohns; glomerulonephritis; other AI

Question 51

Tox azathioprine

Answer 51

- leukopenia, anemia, thrombocytopenia | - NB: 6-MP is degraded by xanthine oxidase, so toxicity is increased by allopurinol

Question 52

Inhibit NF-kappaB; suppress B and T cell fxn by decreasing transcription of many cytokines

Answer 52

glucocorticoids

Question 53

CU glucocorticoids

Answer 53

transplant rejection prophylaxis, AI diseases, inflammation

Question 54

Tox glucocorticoids

Answer 54

hyperglycemia, osteoporosis, central obesity, muscle breakdown, psychosis, acne, HTN, cataracts, peptic ulcers

Question 55

MOA cyclosporine

Answer 55

Calcineurin inhibitor; binds cyclophilin. Blocks T cell activation by preventing IL-2 transcription

Question 56

MOA tacrolimus

Answer 56

Calcineurin inhibitor; binds FK506 binding protein (FKBP); blocks T cell activation by preventing IL-2 transcription

Question 57

MOA sirolimus (rapamycin)

Answer 57

mTOR inhibitor; binds FKBP; blocks T cell activation and B cell differentiation by preventing IL-2 signal transduction

Question 58

MOA azathioprine

Answer 58

Antimetabolite precursor of 6-MP; inhibits lymphocyte proliferation by blocking nucleotide synthesis

Question 59

MOA glucocorticoids

Answer 59

Inhibit NF-kappaB; suppress B and T cell fxn by decreasing transcription of many cytokines